In our effort to control human disease, we created antibiotics. Since the creation of antibiotics we have increased the number of ailments we utilize them for, and have also increased their frequency of use. We no longer use antibiotics to treat only human disease but animal disease as well. Due to the increased use of antibiotics, resistance to these drugs within bacteria has also increased. These new strains of highly drug resistant bacteria are known as "superbugs." Superbugs have become a central concern for the U.S. Centers for Disease Control and Prevention (CDC) and the American public. New and developing solutions include new drugs, improved medical equipment, and smarter data. On January 2, 2013 President Obama signed the bill extending the R&D Tax Credit through the end of 2013 and retroactive for the year 2012. Any U.S. company with costs meeting the tests below is eligible to claim an R&D Tax Credit for up to 13% of related costs. Activities within the niche field of combating superbugs, are strong R&D Tax Credit candidates as they can only combat these new types of antibiotic resistant superbugs with novel and innovative solutions.
Methicillin-resistant Staphylococcus aureus
(MRSA), Clostridium difficile (C. Diff.), and
Vancomycin-resistant Enterococcus faecium (VRE) are just a few
of the major antibiotic resistant bacteria strains. MRSA alone
kills over 19,000 people a year in the United States. Though
these infections are a major problem, most drug companies are
not developing new solutions to these bacteria. There is some
innovative drug research being done, however, many of the
companies focusing their efforts on this area are utilizing
resources beyond developing traditional types of antibiotics.
The time and resources utilized in these efforts should be
eligible for a research and development tax credit.
Federally enacted in 1981, the Research and Development (R&D) Tax Credit allows a credit of up to 13 percent of eligible spending for new and improved products and processes. Qualified research must meet the following four criteria:
Eligible costs include employee wages, cost of supplies, cost of testing, contract research expenses, and costs associated with developing a patent.
Many of the worst diseases in our human history have come from viruses and bacteria which make the jump from animals to humans3,6,12. You only have to think back to avian flu and swine flu (h1n1) to be reminded of this process. The black plague is an example of a bacterial infection which moved across species, with widespread consequences. Large factory farms, because of their low quality feed and high density of animals, regularly utilize varied types and quantities of antibiotics to keep their animals healthy.
In addition to farms, hospitals also have
dense populations and frequent use of antibiotics. Most
hospital stays are coupled with antibiotics either to treat or
prevent bacterial infections. Hospitals were one of the first
places drug resistant bacteria gained widespread notice, staph
infections, and many untreatable, gained mass media attention.
These conditions, dense populations, and frequent use of varied antibiotics seem to have started the ball rolling towards what many health officials are calling the next monumental health disaster, high drug resistant bacteria, or superbugs. These superbugs have been found in both factory farm animals and wild animals near these farms. A recent outbreak of superbugs at the National Institute of Health (NIH) almost shut down all of Baltimore's health system.
It is because of these incidents that
companies are sinking time and resources into creating
solutions for these superbugs. Though most of these solutions
do not focus on new antibiotics8,14. Many of the larger drug
companies have given up on producing antibiotics, due to their
low cost and short run usage.
A (2009) recently created company, Xenex Healthcare Services, has the sole focus of destroying superbugs in hospitals. This method uses a robot with a xenon head which drenches the target area room in ultra-violet light, killing superbugs by destroying its DNA 16.
"The University of Texas MD Anderson Cancer Center, the first hospital to try Xenex's robot, found that it cut bacterial contamination by a factor of 20 and killed 95 percent of the deadly pathogen C. difficile. Studies at other hospitals found C. diff reduction rates of 75 percent. Cooley Dickinson Hospital in Northampton, Mass., uses three rental Xenex robots and says it's seen C. diff infections fall 53 percent16."
Copper and silver surfaces have been shown to be effective in reducing bacteria transmission in public buildings and transportation environments such as bus stations, rail stations, and airports.
Combating superbugs with novel new methods, such as combinations of medical grade manhuka honey (medihoney) and strong antibiotics, which typically are ineffective on their own, but when combined have proven to be a potent cure for antibiotic resistant infections.
Cubist Pharmaceuticals is approaching the problem in a different manner. Rather than setting up new labs, growing and analyzing their own new strains of bacteria they are utilizing bacteria from caves. These bacteria harvested by Hazel Barton an associate professor at Akron University in Ohio, are included in the library of bacteria they already maintain. Cubist utilizes this library of bacteria by analyzing the different strains for the best possible antibiotics, a library made more diverse by including bacteria take from Barton's collection.
Our bodies also produce bacteria fighting substances, which are also being researched to help in the fight against superbugs. One such effort, centered in Germany, has focused on the role sweat plays in preventing and combating infections on and near the surface of your skin. Research conducted by the Max Planck Institute has shown that there are antimicrobial peptides (AMP's) in sweat, which are very effective at long term defense against germs, as they are not able to quickly develop resistance to these AMP's2.
IBM has been working on a nanotech gel called hydrogel that can explode bacteria cells. The hydrogel could be used to coat medical instruments and be used for creams and injections into wounds, causing them to explode and atrophy.
Big Data prediction analysis can use
predictive analysis to track and monitor disease transmission
through a hospitals, nursing homes, and the general
population. Big Data multi agent computer modeling can also
track a disease's geographic origins and match incidents
against possible sources.
The Affordable Care Act (Obamacare) will be penalizing hospitals who readmit patients originally admitted for chronic conditions, mainly heart and lung issues (who comprise over 80% of all medicare enrollees). These penalties will be levied against hospitals regardless of the reason for readmission. Since the number one reason for hospital readmissions is hospital acquired infections, it is reasonable to presume that hospitals will be investing heavily in technologies to reduce these infections and thus reduce readmissions to avoid federal penalties. Penalties levied will be up to 3% of medicare payments to the facility, which for many facilities will be in the multiples of millions in dollars lost.
Media attention, hospitals being penalized
for readmissions, and the CDC identifying this as a major
concern all speak to combating superbugs being a major
priority for innovators with demand for solutions converging
with industry, political, and public calls for help. Each of
the above technologies speaks to this demand with greater
attention likely, going forward.
The superbug problem is one that is global and urgent. The companies that are undertaking research and development of new drugs, procedures, equipment, and software are not only helping to curtail an urgent problem, but they are utilizing never before seen methods and technologies to do so. Any company producing new antibiotics or infection fighting equipment, utilized to combat superbugs are certainly at the forefront of medical research. These lifesaving endeavors can be supported by research and development tax credits.
Charles R Goulding Attorney/CPA, is the President of R&D Tax Savers.
Kenneth Wood is a Tax Analyst with R&D Tax Savers.
Jennifer Reardon is a Project Coordinator with R&D Tax Savers.
|The R&D Tax Credit Aspects of Mechatronics|
|The R&D Tax Credit Aspects of Emotion-Recognition Technology|
|The R&D Tax Credit Aspects of Immunology|
|The R&D Tax Credit Aspects of Arthritis|
|The R&D Tax Credit Aspects of Asthma|
|The R&D Tax Credit Aspects of Telemedicine|
|R&D Tax Credits Enhance Life Science Impact Investing|
|The R&D Tax Credit Aspects of Pediatric Hypertension|
|The R&D Tax Credit Aspects of Parkinsons Disease Technology|
|The R&D Tax Credit Aspects of Legal Medical Marijuana|
|Reaching for the Moon: The R&D Tax Credit Aspects of Conquering Cancer|
|The R&D Tax Credit Aspects of Zika|
|The R&D Tax Aspects of CRISPR-CAS9|
|The R&D Tax Credit Aspects of Bioelectronic Medicine|
|The R&D Tax Credit Aspects of Liquid Biopsy Testing|
|The R&D Tax Credit Aspects of Cryogenics|
|The R&D Tax Aspects of Microbiome Research|
|The R&D Tax Aspects of Mouse Models in Clinical Research|
|The R&D Tax Aspects of Precision Medicine|
|The R&D Tax Aspects of Synthetic Biology|
|The R&D Tax Aspects of Pharmaceutical Packaging|
|New Standards and Regulations Create R&D Tax Credit Opportunities for the Pharmaceutical Packaging Industry|
|The R&D Tax Credit Aspects of Orphan Drugs|
|The R&D Tax Credit Aspects of Blood|
|The R&D Tax Aspects of Regenerative Medicine|
|The R&D Tax Credit Aspects of Environmental Remediation|
|The R&D Tax Credit Aspects of Gastro Technology|
|The R&D Tax Credit Aspects of Multiple Sclerosis|
|The R&D Tax Credit Aspects of Concussion Technology|
|The R&D Tax Credit Aspects of Schizophrenia|
|The R&D Tax Aspects of Cancer Treatment|
|The R&D Tax Aspects of the New FDA Mobile Apps Requirements|
|The R&D Tax Credit Aspects of the Medical Software Industry|
|The R&D Tax Aspects of Computer Enabled Human Identification|
|The R&D Tax Credit Aspects of Heart Disease|
|The R&D Tax Credit Aspects of Biological Drugs|
|The R&D Tax Credit Aspects of Novel Uses for Genetically Engineered Organisms|
|The R&D Tax Aspects of Respiratory Diseases|
|The R&D Tax Credit Aspects of Cognitive Computing|
|The R&D Tax Credit Aspects of Cosmetics|
|The R&D Tax Credit Aspects of Major Life Science Benefactors|
|The R&D Tax Credit Aspects of the Health Cloud|
|The R&D Tax Credit Aspects of Autism|
|The R&D Tax Credit Aspects of 3D Bioprinting|
|The R&D Credit Aspects of Cell Therapy|
|The R&D Tax Credit Aspects of Sugar Substitution and Reduction in Food Products|
|The R&D Tax Credit Aspects of Gluten-Free Foods|
|R&D Tax Credit Aspects of Sleep Innovation|
|R&D Tax Credit Aspects of Medical Robotics|
|The R&D Tax Aspects of Neuroscience|
|The R&D Tax Credit Aspects of Hearing Technology|
|The R&D Tax Credit Aspects of Eye Disease|
|The R&D Tax Credit Aspects of Dermatology Innovation|
|The R&D Tax Credit Aspects of Bioinformatics|
|The R&D Tax Aspects of Lab Equipment and Instrumentation|
|The R&D Tax Aspects of Salt Reduction|
|The R&D Tax Aspects of Generic Drugs|
|R&D Tax Credit Fundamentals|
|The R&D Tax Credit Aspects of Alzheimers|
|The R&D Tax Aspects of Diabetes|
|The R&D Tax Aspects of Brain Mapping|
|R&D Tax Credit Aspects of Human Body Weight|